Emerging Understanding of Multiscale Tumor Heterogeneity

Michael J. Gerdes(General Electric (United States)), Anup Sood(General Electric (United States)), Christopher J. Sevinsky(General Electric (United States)), Andrew D. Pris(General Electric (United States)), Maria I. Zavodszky(General Electric (United States)), Fiona Ginty(General Electric (United States))
Frontiers in Oncology
December 18, 2014
Cited by 118Open Access
Full Text

Abstract

Cancer is a multifaceted disease characterized by heterogeneous genetic alterations and cellular metabolism, at the organ, tissue, and cellular level. Key features of cancer heterogeneity are summarized by 10 acquired capabilities, which govern malignant transformation and progression of invasive tumors. The relative contribution of these hallmark features to the disease process varies between cancers. At the DNA and cellular level, germ-line and somatic gene mutations are found across all cancer types, causing abnormal protein production, cell behavior, and growth. The tumor microenvironment and its individual components (immune cells, fibroblasts, collagen, and blood vessels) can also facilitate or restrict tumor growth and metastasis. Oncology research is currently in the midst of a tremendous surge of comprehension of these disease mechanisms. This will lead not only to novel drug targets but also to new challenges in drug discovery. Integrated, multi-omic, multiplexed technologies are essential tools in the quest to understand all of the various cellular changes involved in tumorigenesis. This review examines features of cancer heterogeneity and discusses how multiplexed technologies can facilitate a more comprehensive understanding of these features.


Related Papers

No related papers found

Powered by citation graph analysis